The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase Ib study of oral PPARγ agonist efatutazone (CS-7017) in combination with erlotinib in Korean patients with metastatic or unresectable locally advanced non-small cell lung cancer (NSCLC) who progressed after first-line therapy.
Sang-We Kim
No relevant relationships to disclose
Chang-Min Choi
No relevant relationships to disclose
Dae Ho Lee
No relevant relationships to disclose
Jae Cheol Lee
No relevant relationships to disclose
Cheolwon Suh
No relevant relationships to disclose
Jung Shin Lee
No relevant relationships to disclose